Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

azine). Alexza is developing AZ-001 to treat patients suffering from acute migraine headaches. Alexza requested an end of Phase 2 meeting with the FDA during the second quarter of 2008 and has been granted this meeting for the third quarter of 2008.

-- AZ-104 (Staccato loxapine). Alexza is developing AZ-104 to treat patients suffering from acute migraine headaches. AZ-104 is a lower dose version of AZ-004. In March 2008, the Company announced initial results of an in-clinic, multi-center randomized, double-blind, single administration, placebo controlled Phase 2a proof-of-concept clinical trial in 168 migraine patients with or without aura. Three doses of AZ-104 (1.25, 2.5 and 5 mg) were evaluated against placebo in the clinical trial. Using the IHS 4-point rating scale, the primary efficacy endpoint was pain-relief response at 2 hours post-administration. AZ-104 met the primary efficacy endpoint of the clinical trial for the two highest doses of the drug compared to placebo. Statistically significant improvements in pain response were observed in 76.7% of patients at the 5 mg dose (p= 0.02), 79.1% of patients at the 2.5 mg dose (p = 0.01) and 67.4% of patients at the 1.25 mg dose (p = 0.18), compared to 51.3% of patients receiving placebo. Using survival analysis for pain relief response, all three dose groups were statistically superior (p < 0.05) to placebo during the 4-hour post-treatment time period that the patients remained in the clinic.

Alexza's original IND for Staccato loxapine was filed with the Division of Neuropharmacological Drug Products of the FDA. In July 2005 the FDA reorganized this division into two new divisions, the Division of Psychiatry Products, or DPP, and the Division of Neurology Products, or DNP. The Staccato loxapine IND was transferred to the DPP, as the AZ-004 development program is for a psychiatric indication. Under that IND, Alexza was allowed to conduct the first patient study in migraine patients, the Phase 2a proo
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... July 10, 2014  The U.S. Department of Health ... to University Hospitals (UH) Case Medical Center Seidman Cancer ... model aimed at improving care for patients with complex ... project will test a unique model developed at UH ... disease, significant comorbidities, or demonstrated need for high health ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., a ... has launched the FreeRunner™ knee brace with new ... from patella mal-tracking return to active lifestyles.  FreeRunner,s ... other braces, providing support when patients need it ... they don,t. Patellofemoral issues are the ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... 1 Allen Medical Systems, a Hill-Rom company, (NYSE: ... Spotlight Series showcasing interviews with top orthopaedic surgeons. Carlos ... Institute, is the featured surgeon and is recognized for ... Intraoperative Arm Positioner for elbow fractures, scopes and clavicle ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE), a ... as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) ... delivery, announced today that Patrick T. Mooney, M.D., Chairman ... Annual JMP Securities Healthcare Conference on Tuesday, October 6, ...
Cached Medicine Technology:Allen Medical Systems Announces Surgeon Spotlight Series Interview 2Allen Medical Systems Announces Surgeon Spotlight Series Interview 3Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 2
(Date:7/10/2014)... Ticketability.com has a wide array of tickets for the ... San Diego are being added to the inventory. The star ... newly added September 28 show is drawing a great deal ... to view the selection of discounted seats at Ticketability.com. , ... to the general public on July 18 at 10:00 a.m. ...
(Date:7/10/2014)... 10, 2014 Thousands of researchers ... Copenhagen this July 13-17 to reveal the latest ... closer to breakthroughs in dementia science. The Alzheimer’s ... conference of its kind. , As part of ... a catalyst for generating new knowledge about dementia ...
(Date:7/10/2014)... One week ahead of its annual ... today it will extend compensation benefits to workers from ... workers displaced as a result of factory remediation, effective ... resulted in the closure of five factories for remediation. ... immediate safety concerns. In May, the Alliance—in a 50/50 ...
(Date:7/10/2014)... July 10, 2014 Register to download ... recently streamed the live webinar ‘Capitalizing on the Shifting ... a group of several M&A experts in the energy ... broader energy transaction marketplace. These experts shared their insights ... deal market in this sector has been revitalized. This ...
(Date:7/10/2014)... According to a new market research report "Man-Portable ... Application (Software Defined Radios, SATCOM, Encryption, Smartphones, Homeland ... Europe, the Middle East & ROW) - Forecast ... is estimated to be $30.15 billion in 2014 ... 5.56% to reach $39.52 billion by 2019 ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
... ... becoming more popular and may even be permanent alternatives to surgery. These treatments are ... Advancements in technology and techniques are also making these treatments permanent rather than temporary solutions. ... Los Angeles, CA (PRWEB) ...
... ... More than six out of every ten Americans have problems sleeping. Based ... National Institutes of Health, National Science Foundation, The Deafness Foundation, and NASA, ... in sleep. Now, Horowitz and NeuroPop launch RealSleep, new products that harness ...
... ... organization by training your staff on the ten distinct warning signs that foretell violence ... issue without sensationalizing, but by approaching the subject directly and honestly. , ... (PRWEB) May 18, 2010 -- ...
... who received hypofractionated stereotactic radiotherapy for their recurrent ... at Thomas Jefferson University. Not only ... patients do not experience side effects commonly seen ... researchers found. They believe these findings, reported online ...
... ... supplement plans are changing once again. Insurance companies selling Medicare supplements must begin offering these ... ... Medicare supplement insurance from standardization to modernization has taken place during the last twenty years. ...
... actually help folks take it easier, be happier, researcher says , ... to show the sad signs of aging after you hit 50, ... years go by. , On average, people reported being less worried ... in the years after their 20s. Perhaps most surprisingly, people in ...
Cached Medicine News:Health News:Dr. Alexander Rivkin's Pioneering Non-Surgical Nose and Eye Transformations Are Making Headlines and May Be Permanent Solutions 2Health News:New Hope for the Sleepless: RealSleep Uses Sound To Help Troubled Sleepers Go To Sleep Faster and Stay Asleep Longer 2Health News:New Hope for the Sleepless: RealSleep Uses Sound To Help Troubled Sleepers Go To Sleep Faster and Stay Asleep Longer 3Health News:Kantola Productions Releases Workplace Violence Prevention Training Video 2Health News:Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer 2Health News:Well-tolerated radiotherapy provides longer life to patients with recurrent brain cancer 3Health News:The New 2010 Modernized Medicare Supplement Plans: Positive Changes in the Midst of Health Care Reform 2Health News:The New 2010 Modernized Medicare Supplement Plans: Positive Changes in the Midst of Health Care Reform 3Health News:The New 2010 Modernized Medicare Supplement Plans: Positive Changes in the Midst of Health Care Reform 4Health News:The New 2010 Modernized Medicare Supplement Plans: Positive Changes in the Midst of Health Care Reform 5Health News:Survey Finds Those Over 50 Are Less Stressed 2Health News:Survey Finds Those Over 50 Are Less Stressed 3
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
The MediLive ImageBox is the first, easy-to-use digital,recording device that integrates with the surgical microscope and video camera., ,It simplifies image capturing by burning the still imag...
With MediLive MindStream you can make, cut and edit digital videos, add commentaries and notes, and save them. MediLive MindStream - intuitive user interface and high-resolution monitor all in one....
... non-mydriatic fundus camera increases ... of fundus imaging. Compact, ... set the standard in ... a unique combination of ...
Medicine Products: